billHR8871Event Tuesday, May 19, 2026Analyzed

DME Scammer Prevention Act of 2026

Neutral

Summary

The DME Scammer Prevention Act of 2026 (HR8871) is an early-stage bill referred to two committees. It mandates electronic submission and a 90-day filing deadline for certain DME claims under Medicare. No funding is authorized, and the bill is procedural with no direct market impact on any publicly traded company at this stage.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR8871 is an early-stage procedural bill with no funding or direct market impact.
  • 2.No publicly traded company is uniquely affected; compliance costs are immaterial.
  • 3.Investors should monitor committee action but no actionable trade signal exists.

Market Implications

No market implications at this stage. The bill is purely administrative and does not affect any sector's revenue or cost structure. Investors should ignore until committee action indicates momentum.

Full Analysis

On May 19, 2026, Rep. Aaron Bean (R-FL) introduced HR8871, the DME Scammer Prevention Act of 2026. The bill was referred to the House Committees on Energy and Commerce and Ways and Means. It is in the earliest legislative stage with no hearings, markups, or votes scheduled. The bill amends the Social Security Act to require electronic submission of claims for specified DME items (as defined by a CMS Master List) and imposes a 90-day filing deadline for applicable items. No funding is authorized or appropriated; the bill imposes administrative requirements on Medicare providers and suppliers. The legislative path is long: it must pass both committees, the full House, the Senate, and be signed into law. Given the sponsor is a junior member and the bill is procedural, near-term market impact is negligible. No publicly traded company is directly named or uniquely affected by these administrative changes. DME suppliers include diversified healthcare companies, but the compliance costs are immaterial relative to their revenue. The bill does not alter reimbursement rates, coverage, or market access for any specific product or company.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderMay 19, 2026

Integrating Financial Technology Innovation into Regulatory Frameworks

This executive order directs federal financial regulators to review and streamline regulations that hinder fintech innovation, particularly for small and emerging firms, and requests the Federal Reserve to evaluate expanding access to its payment accounts and services for non-bank and digital asset firms. It aims to reduce barriers to entry and encourage partnerships between fintech firms and traditional financial institutions, with specific deadlines for reviews and reports.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.